Instinct Bio Technical Company Holdings Inc. has secured a proposed $150 million equity purchase facility to scale its regenerative medicine platform and expand its longevity ecosystem.
返回
Instinct Bio secures $150 million equity facility for regenerative medicine
Instinct Bio Technical Company Holdings Inc. has secured a proposed $150 million equity purchase facility to scale its regenerative medicine platform and expand its longevity ecosystem.
Instinct Bio (Nasdaq: BIOT) entered an indicative term sheet for an equity purchase facility that would allow the company to sell up to $150 million of its common stock over three years, the company said Tuesday. The facility gives Instinct Bio the right, but not the obligation, to direct share purchases from time to time, with pricing based on the volume-weighted average price of its stock on each purchase date less a specified discount.
"The structure is intended to allow the company to access capital opportunistically while managing its financing needs over time," Tomoki Nagano, chief executive officer of Instinct Bio, said.
The proposed facility follows Instinct Bio's recent business combination with Relativity Acquisition Corp., which listed the company on the Nasdaq. Proceeds will accelerate scaled development of its regenerative medicine platform, fund working capital and support strategic acquisitions to expand its longevity ecosystem, the company said.
Instinct Bio focuses on regenerative medicine, longevity-related technologies and advanced therapeutic platforms, combining proprietary stem cell-based therapies with in-house manufacturing and commercial operations across Asia and the US. The biotech sector has seen heightened investor interest in longevity and regenerative medicine, with global longevity research funding exceeding $40 billion in 2025, according to industry data. The company's Nasdaq listing and this capital facility position it to compete for market share against larger players such as Vertex Pharmaceuticals and CRISPR Therapeutics, which have established cell therapy programs but lack Instinct Bio's dedicated longevity focus.
The equity facility, if finalized, would provide Instinct Bio with discretionary capital to pursue acquisitions and R&D without the pressure of near-term fundraising. The company did not disclose its current cash position or specify a timeline for executing the definitive transaction documents.
This article is for informational purposes only and does not constitute investment advice.
